Eliminating residual neuromuscular blockade: a literature review

Mogen Frenkel,Cynthia A. Lien

DOI: https://doi.org/10.21037/atm-23-1743

IF: 3.616

2024-06-26

Annals of Translational Medicine

Abstract:Keywords: Neuromuscular blockade (NMB); quantitative monitoring; sugammadex; postoperative residual neuromuscular blockade; reversal of residual neuromuscular blockade

oncology,medicine, research & experimental

What problem does this paper attempt to address?

Residual Neuromuscular Block Remains a Safety Concern for Perioperative Healthcare Professionals: A Comprehensive Review

Franziska Elisabeth Blum,Andrew R Locke,Naveen Nathan,Jeffrey Katz,David Bissing,Mohammed Minhaj,Steven B Greenberg

DOI: https://doi.org/10.3390/jcm13030861

2024-02-01

Abstract:Residual neuromuscular block (RNMB) remains a significant safety concern for patients throughout the perioperative period and is still widely under-recognized by perioperative healthcare professionals. Current literature suggests an association between RNMB and an increased risk of postoperative pulmonary complications, a prolonged length of stay in the post anesthesia care unit (PACU), and decreased patient satisfaction. The 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade provide guidance for the use of quantitative neuromuscular monitoring coupled with neuromuscular reversal to recognize and reduce the incidence of RNMB. Using sugammadex for the reversal of neuromuscular block as well as quantitative neuromuscular monitoring to quantify the degree of neuromuscular block may significantly reduce the risk of RNMB among patients undergoing general anesthesia. Studies are forthcoming to investigate how using neuromuscular blocking agent reversal with quantitative monitoring of the neuromuscular block may further improve perioperative patient safety.
Residual neuromuscular block in the postanaesthesia care unit: a single-centre prospective observational study and systematic review

Veerle Bijkerk,Piet Krijtenburg,Tessa Verweijen,Jörgen Bruhn,Gert Jan Scheffer,Christiaan Keijzer,Michiel C Warlé

DOI: https://doi.org/10.1016/j.bja.2024.07.043

2024-10-22

Abstract:Background: Concerns regarding residual neuromuscular block (RNMB) have persisted since the introduction of neuromuscular blocking agents, with reported incidences in the 21st century up to 50%. Advances in neuromuscular transmission (NMT) monitoring and the introduction of sugammadex have addressed this issue, but the impact of these developments remains unclear. Methods: This prospective observational study evaluated RNMB in 500 surgical patients in a large Dutch teaching hospital with readily available quantitative NMT monitoring and reversal agents. The anaesthetic technique and intraoperative NMT monitoring were independently chosen by the attending anaesthesiologist. Acceleromyography was performed upon arrival in the PACU for patients who received nondepolarising neuromuscular blocking agents. RNMB was defined as a train-of-four ratio (TOFR) <0.9. A systematic review was conducted to analyse trends in RNMB in contemporary practice. Results: Out of 500 patients, 11 (2.2%) had a TOFR <0.9. Intraoperative NMT monitoring was performed in 77.6% of patients, and sugammadex was administered to 38% of patients. No patient received neostigmine. The only difference was an automatically recorded TOFR ≥0.9 at the end of surgery in 61.1% in the non-RNMB group compared with 18.2% in the RNMB group (P=0.009). Our systematic review identified incidences ranging from 3.5% to 53.3% since 2000, with a decreasing trend in Europe and North America. Conclusions: The incidence of residual neuromuscular block in the PACU was 2.2%. This suggests significant improvement in the prevention of residual neuromuscular block and stresses the importance of rigorous neuromuscular transmission monitoring and adequate use of reversal agents.
Driving Residual Neuromuscular Blockade to Zero: Precision Matters

Ken B. Johnson

DOI: https://doi.org/10.1213/ane.0000000000007064

IF: 6.627

2024-08-18

Anesthesia & Analgesia

Abstract:Professional practice guidelines and consensus statements developed during the last 10 years recommend the use of quantitative neuromuscular monitors (NMMs) when neuromuscular blocking (NMB) drugs are used. 1–4 In the era of sugammadex, anesthesia providers may wonder why to use a more complex monitor when sugammadex is such an effective reversal agent unless an agent like atracurium is used? Advanced monitoring techniques are an interesting academic exercise but can be a nuisance in a busy clinical practical. This level of skepticism may present a significant hurdle to their widespread adoption.

anesthesiology
Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity

Alexis Schneider,Martin R Tramèr,Gleicy Keli-Barcelos,Nadia Elia

DOI: https://doi.org/10.1016/j.bja.2024.05.015

2024-07-11

Abstract:Background: Efficacy and safety of sugammadex for the reversal of neuromuscular blocking agents (NMBAs) in patients with neuromuscular diseases remains unclear. We summarised the available evidence and evaluated the quality of data reporting and the validity of published reports. Methods: We searched for reports (any design) on the usage of sugammadex (any regimen) for the reversal of an NMBA in patients (any age) with any neuromuscular disease. We used a modified CARE checklist (maximum score 23) to assess the quality of data reporting and an original specific validity checklist (maximum score 41) that was developed through a Delphi process. Results: We retrieved 126 observational reports (386 patients). Most dealt with myasthenia gravis patients receiving rocuronium. The train-of-four ratio returned to ≥0.9 in 258 of 265 (97.4%) patients in whom neuromonitoring was used. Adverse events occurred in 14 of 332 (4.2%) patients in whom adverse events were reported as present or absent. In 90 case reports, the median score of the 23-point CARE checklist was 13.5 (inter-quartile range [IQR] 11-16). In all 126 reports, the median score of the 41-point validity checklist was 23 (IQR 20-27). Scores were positively correlated. Conclusions: These uncontrolled observations (of mainly low to moderate quality and validity) do not allow confident assessment of the efficacy and safety of sugammadex for the reversal of NMBAs in patients with neuromuscular diseases. Reporting of observational data should follow established guidelines, include specific information to ensure validity, and emphasise what the new data add to current knowledge. Systematic review protocol: PROSPERO 2019 (CRD42019119924).
Sugammadex vs Neostigmine, a Comparison in Reversing Neuromuscular Blockade: A Narrative Review

Shafaque Maqusood,Amol Bele,Neeta Verma,Sambit Dash,Dushyant Bawiskar

DOI: https://doi.org/10.7759/cureus.65656

2024-07-29

Cureus

Abstract:The use of neuromuscular blocking agents (NMBA) has grown due to the development of laparoscopic and minimally invasive procedures. Respiratory insufficiency, an elevated risk of aspiration, postoperative pulmonary complications, and subsequent reintubation are among the risks linked to the residual block. The normal clinical practice calls for the pharmacologic "reversal" of these agents with either sugammadex or neostigmine prior to extubation. The administration of neostigmine is linked to a number of potential complications. In response, anaesthesiologists have begun to prescribe sugammadex more frequently for treating residual block and reversing blockade with NMBA. This review article compares and assesses neostigmine and sugammadex thoroughly in order to determine the extent to which they work as agents to reverse neuromuscular blockade. The review's findings highlight sugammadex's considerable advantages - Sugammadex's ability to quickly and reliably achieve desired train-of-four (TOF) ratios - over neostigmine in reversing neuromuscular blockade in a variety of surgical settings. In contrast, neostigmine's limitations regarding efficacy and rate of reversal were consistently noted in all of the reviewed studies, despite the fact that it is still widely used due to its lower cost and extensive clinical experience. Sugammadex is a superior option for reversing neuromuscular blockade, but incorporating it into standard clinical practice necessitates carefully weighing its potential benefits and drawbacks. Sugammadex provides notable benefits over neostigmine in terms of speed, predictability, and safety.
[Problem of neuromuscular block reversion: neostigmine and sugammadex]

V M Mizikov,V I Stamov,Iu V Deshko,A Iu Ialich

Abstract:The review covers the history of neuromuscular block reversal. It states that indications for decurarization have been changed due to the extremely high rate of residual curarization even after the use of average-acting myorelaxants. The paper provides the pharmacological characteristics of sugammadex, a new selective relaxant-binding agent for aminosteroids (rocuronium and vecuronium) with the unique mechanism of action. It also gives data on the efficacy and safety of sugammadex versus anticholinesterase agents and estimates the prospects for its clinical application.
Trends in the use of neuromuscular blocking agents, reversal agents and neuromuscular transmission monitoring: a single-centre retrospective cohort study

Piet Krijtenburg,Arjen de Boer,Lori D. Bash,Gert Jan Scheffer,Christiaan Keijzer,Michiel C. Warlé

DOI: https://doi.org/10.1186/s13741-024-00382-y

2024-03-28

Perioperative Medicine

Abstract:Residual neuromuscular blockade (rNMB) remains a persistent and preventable problem, with serious risks.

surgery,anesthesiology
The effect of sugammadex on patient morbidity and quality of recovery after general anaesthesia: a systematic review and meta-analysis

Benjamin L Olesnicky,Clare Farrell,Phoebe Clare,Shelly Wen,Kate Leslie,Anthony Delaney

DOI: https://doi.org/10.1016/j.bja.2023.10.032

Abstract:Background: Residual neuromuscular block is associated with increased patient morbidity. Therefore prevention of residual neuromuscular block is an important component of general anaesthesia where neuromuscular blocking agents are used. Whereas sugammadex improves reversal based on neuromuscular twitch monitoring parameters, there have been no prospective, adequately powered definitive studies demonstrating that sugammadex is also associated with less patient morbidity. Methods: We performed a systematic review of randomised trials comparing sugammadex with anticholinesterase-based reversal or placebo reversal that reported important patient outcomes beyond the postanaesthesia care unit. Results: We identified 43 articles, including 5839 trial participants. Only one trial reported days alive and out of hospital to 30 days (DAOH-30), which showed that the number of DAOH-30 was similar in those allocated to sugammadex compared with neostigmine-based reversal (25 days [19-27] vs 24 days [21-27], median difference 0.00 [-2.15 to 2.15]). Pooled analyses of data from 16 trials showed an estimated odds ratio (OR) for postoperative pulmonary complications of 0.67 (95% confidence interval 0.47-0.95) with sugammadex use. Pooled analysis showed that pneumonia (eight trials OR 0.51 [0.24-1.01] with sugammadex use), hospital length of stay (23 trials, mean difference -0.31 [-0.84 to 0.22] with sugammadex use), and patient-reported quality of recovery (11 trials, varied depending on metric used) are similar in those allocated to sugammadex vs control. The difference seen in mortality (11 trials, OR 0.39 [0.15-1.01] with sugammadex use) would be considered to be clinically significant and warrants further investigation, however, the rarity of these events precludes drawing definitive conclusions. Conclusion: Although few trials reported on DAOH-30 or important patient outcomes, sugammadex is associated with a reduction in postoperative pulmonary complications, however, this might not translate to a difference in hospital length of stay, patient-reported quality of recovery, or mortality. Clinical trial registration: PROSPERO database (CRD42022325858).
The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: A systematic review

Guangyu Liu,Rui Wang,Yanhong Yan,Long Fan,Jixiu Xue,Tianlong Wang

DOI: https://doi.org/10.1038/s41598-017-06159-2

2017-07-18

Abstract:The aim of this study is to evaluate the efficacy and safety of sugammadex for reversing neuromuscular blockade in pediatric patients. MEDLINE and other three Databases were searched. Randomized clinical trials were included if they compared sugammadex with neostigmine or placebo in pediatric patients undergoing surgery involving the use of rocuronium or vecuronium. The primary outcome was the time interval from administration of reversal agents to train-of-four ratio (TOFr, T4/T1) > 0.9. Incidences of any drug-related adverse events were secondary outcomes. Trial inclusion, data extraction, and risk of bias assessment were performed independently. Mean difference and relative risk were used as summary statistics with random effects models. Statistical heterogeneity was assessed by the I2 statistic. Funnel plot was used to detect publication bias. Ten studies with 580 participants were included. Although considerable heterogeneity (I2 = 98.5%) was detected in primary outcome, the results suggested that, compared with placebo or neostigmine, sugammadex can reverse rocuronium-induced neuromuscular blockade more rapidly with lower incidence of bradycardia. No significant differences were found in the incidences of other adverse events. Compared with neostigmine or placebo, sugammadex may reverse rocuronium-induced neuromuscular blockade in pediatric patients rapidly and safely.
Postoperative residual curarisation: complication or malpractice?

G Cammu

Abstract:Neuromuscular blocking drugs are often used in anaesthesia; in some types of surgery, their continuous infusion is indicated to limit the otherwise high incidence of movement. A large amount of postoperative residual curarisation is found after a single bolus, but more especially when continuous infusions are used in healthy patients and even more so in those with organ dysfunction or undergoing special types of surgery. Therefore, one should always optimise the dose requirements over time using neuromuscular transmission monitoring. Such monitoring should also help the clinician to antagonise selectively the neuromuscular block at the end of surgery. One should probably avoid routine antagonisation, especially in certain subgroups of patients, until a selective and safe reversal agent has been developed. At present, then, the only objective and reliable guide to facilitating the decision for selective antagonisation is the neuromuscular transmission monitor. Recent data and editorials warning about postoperative residual curarisation after boluses and infusions of neuromuscular blocking drugs have made residual curarisation one of the most feared complications in anaesthesia. There may be a consequent issue of malpractice if neuromuscular transmission monitoring is not used and/or pharmacological antagonisation is not performed.
The Incidence of Residual Neuromuscular Block in Pediatrics: A Prospective, Pragmatic, Multi-institutional Cohort Study

Debra J Faulk,Joelle B Karlik,Kim M Strupp,Stephanie M Tran,Mark Twite,Sorin J Brull,Myron Yaster,Thomas M Austin

DOI: https://doi.org/10.7759/cureus.56408

2024-03-18

Cureus

Abstract:Introduction Residual neuromuscular block, defined as a quantitatively measured train-of-four ratio (TOFr) <0.9, is common postoperatively. Using a pragmatic trial design, we hypothesized that qualitative and/or clinical assessment of neuromuscular block would inadequately detect residual block following antagonism with neostigmine or sugammadex. Method After IRB approval and written informed consent, 74 children (aged 2-17 years), undergoing elective surgery and receiving rocuronium, were prospectively enrolled in the study at Children's Hospital Colorado and Children's Healthcare of Atlanta. Routine clinical practice at both institutions consisted of clinical signs and/or qualitative assessment with peripheral nerve stimulators. Children at the Colorado hospital routinely received sugammadex antagonism; whereas children at the Atlanta hospital received neostigmine. Residual neuromuscular block was assessed postoperatively using quantitative electromyography. If TOFr was <0.9, patients received sugammadex until TOFr ≥0.9. Result Qualitative and clinical assessment failed to detect residual block in 29.7% of patients in the neostigmine reversal cohort (adjusted odds ratio (aOR) 29.8, 95% confidence interval (CI): 2.7 to 5,559.5, p-value = 0.002). No residual block was detected in the sugammadex reversal cohort. A correlation between increasing patient weight and incidence of postoperative residual block was observed in the neostigmine cohort (aOR 1.05, 95% CI: 1.02 to 1.10, p-value = 0.002). Conclusion Qualitative and/or clinical assessment of neuromuscular block inadequately detects residual block following neostigmine antagonism.
Improving Neuromuscular Monitoring Through Education-Based Interventions and Studying Its Association With Adverse Postoperative Outcomes: A Retrospective Observational Study

Shane G. Carr,Jacob C. Clifton,Robert E. Freundlich,Leslie C. Fowler,Edward R. Sherwood,Matthew D. McEvoy,Amy Robertson,Brent A. Dunworth,Karen Y. McCarthy,Matthew S. Shotwell,Miklos D. Kertai

DOI: https://doi.org/10.1213/ane.0000000000006722

IF: 6.627

2024-02-19

Anesthesia & Analgesia

Abstract:See Article, page 514 Postoperative pulmonary complications (PPCs) are frequent and costly complications, with a reported incidence of up to 20% after noncardiac surgery and a cost of approximately $52,000 USD per occurrence. 1 PPCs are also associated with increased mortality and an increased average hospital length of stay of 5.5 days. 2 , 3 PPCs are strongly linked with decreased respiratory function, which often occurs in the postoperative period as the result of residual neuromuscular blockade (rNMB) related to incomplete neuromuscular blockade (NMB) reversal. 4 Sugammadex has been shown in one multicenter observational study to be associated with a reduced risk of PPCs, including pneumonia and respiratory failure when compared with neostigmine. 5 This risk reduction has been reported to be more pronounced in the patients at the highest risk of PPCs. 6

anesthesiology
Clinical Effectiveness and Cost-Effectiveness of Sugammadex for Reversal of Neuromuscular Block: A Rapid Health Technology Assessment

P. Men,X. Gu,H. Zhang,S. Zhai

DOI: https://doi.org/10.1016/j.jval.2018.07.042

IF: 5.156

2018-01-01

Value in Health

Abstract:Sugammadex (Bridion®), a modifiedγ-cyclodextrin, is the first selective relaxant binding agent for the reversal of neuromuscular blockade (NMB). This study aimed to efficiently evaluate the clinical effectiveness and cost-effectiveness of sugammadex to meet the needs of decision making. We systematically searched the databases (including PUBMED, EMBASE, the Cochrane Library, CNKI, WanFang database) and websites of Health Technology Assessment (HTA) organizations to identify systematic reviews, pharmacoeconomic studies and HTA reports of sugammadex versus placebo or active comparators for reversal of NMB. After independent study selection, data extraction and quality assessment, included studies were comprehensively analyzed as appropriate. Seven systematic reviews, five pharmacoeconomic studies and two HTA reports were included. The results suggested that, compared with neostigmine or placebo, sugammadex significantly reduced the time to reverse rocuronium or vecuronium-induced neuromuscular blockade (range of weighted mean difference: -46.36 to -10.22 min, P<0.05) and the incidence of postoperative residual blockade (range of risk ratio: 0.40 to 0.46, P<0.05) in adults. Sugammadex did not increase the incidence of general adverse effects compared to placebo, and had similar or significantly lower incidence of general adverse events, postoperative nausea or vomiting and respiratory events, compared with neostigmine. Sugammadex was also associated with significantly lower risk of bradycardia and postoperative weakness. In comparison with neostigmine(+glycopyrrolate), sugammadex was a cost-effective or even cost-saving option, which was resulted from various clinical benefits including remarkable less time to discharge to surgical ward, shorter duration of operating room occupancy, and avoiding costly postoperative complications such as residual curarization-related intensive care unit admission. In the management of NMB, sugammadex was proved to be superior to neostigmine by state-of-the-art evidence, not only for the better efficacy and safety profiles, but also for its favorable economic impacts on patients and medical resource utilization.
Reversal of neuromuscular block with neostigmine and sugammadex: a retrospective cohort study in two centers using different types of neuromuscular monitoring

Cyrus Motamed,Bernard Trillat,Marc Fischler,Morgan le Guen,Jean Louis Bourgain

DOI: https://doi.org/10.1007/s10877-024-01192-9

2024-07-20

Abstract:This bicentric retrospective cohort study evaluates reversal of muscle relaxation in real life achieved either by neostigmine or sugammadex in two hospitals using different types of neuromuscular monitoring (acceleromyography and kinemyography). The research question concerns compliance with recommendations. Patients who underwent an abdominal surgery under general anesthesia in the period from January 2017 through December 2020 with a neuromuscular block with rocuronium were included in the study. Data were extracted from the Centricity anesthesia information management system. In total, 2242 patients were assessed: 459 in center 1 (61 having received neostigmine and 398 sugammadex) and 1783 in center 2 (531 and 1252, respectively). Patients' characteristics differed between centers, with more high-risk patients in center 1. The mean train-of-four (TOF) ratio after supramaximal current determination (supramaximal threshold) was higher in center 1 (p < 0.001). Most patients received neostigmine while the TOF ratio was < 40% (68.6% in center 1 and 62.4% in center 2), while extubation was performed while the TOF ratio was > 90% in 61.0% in center 1 and in 32.1% in center 2 (p < 0.001). Patients received sugammadex irrespective of the number of responses to TOF before reversal, and extubation was performed while the TOF ratio was > 90% in 85.0% in center 1 and in 53.6% in center 2 (p < 0.001). No side effect was encountered. Despite guidelines for the TOF ratio before extubation, recommendations were not adequately respected and more vigilance is mandatory. The TOF test before use gave values that were 100% far apart with an underestimation with acceleromyography and an overestimation using kinemyography.
Safety of sugammadex for reversal of neuromuscular block

Ghm Honing,C H Martini,A Bom,M van Velzen,M Niesters,Lphj Aarts,A Dahan,M Boon

DOI: https://doi.org/10.1080/14740338.2019.1649393

Abstract:Introduction: Sugammadex is a modified cyclodextrin that is able to reverse neuromuscular block induced by aminosteroidal neuromuscular blocking drugs. Compared to reversal with neostigmine, it reverses neuromuscular block quicker and more predictable and without cholinergic side effects. However, there have been concerns about sugammadex ability to bind other drugs and its effects on QT interval and clotting times. In addition, sugammadex might induce hypersensitivity reactions more frequently than initially anticipated. This review summarizes current evidence with regard to these and other safety aspects of sugammadex. Areas covered: This review provides an overview of the efficacy of sugammadex in various patient populations, evaluates potential interactions with other drugs and discusses adverse effects and reactions that have been reported in the literature. Expert opinion: Sugammadex quickly reverses aminosteroid neuromuscular block with less side effects compared to neostigmine. As such, it has the potential to significantly reduce the incidence of residual neuromuscular block and to improve postoperative pulmonary outcome. Current safety concerns mainly focus on hypersensitivity reactions and cardiac arrhythmias. Although the absolute risk for these events is low, ongoing vigilance and research in this area are needed.
Evaluation of a Protocol for the Management of Maintenance and Reversal of Rocuronium Block Using Neostigmine or Sugammadex

Stephan R Thilen,Tinny Liang,Timothy N Kruse,Kevin C Cain,Miriam M Treggiari,Sanjay M Bhananker

DOI: https://doi.org/10.1213/ANE.0000000000006510

2023-06-01

Abstract:Background: Postoperative residual neuromuscular blockade (PRNB) is defined as an adductor pollicis train-of-four ratio (TOFR) <0.9. It is a common postoperative complication when nondepolarizing muscle relaxants are either not reversed or reversed with neostigmine. PRNB has been reported in 25% to 58% of patients who receive intermediate-acting nondepolarizing muscle relaxants, and it is associated with increased morbidity and decreased patient satisfaction. We conducted a prospective descriptive cohort study during the implementation of a practice guideline that included the selective use of sugammadex or neostigmine. The primary study aim of this pragmatic study was to estimate the incidence of PRNB at arrival to the postanesthesia care unit (PACU) when the practice guideline is followed. Methods: We enrolled patients undergoing orthopedic or abdominal surgery requiring neuromuscular blockade. Rocuronium administration was guided by surgical requirements and based on ideal body weight, with dose reductions for women and/or age >55 years. Only qualitative monitoring was available to the anesthesia providers, and selection of sugammadex or neostigmine was guided by tactile assessments of the response to train-of-four (TOF) stimulation by a peripheral nerve stimulator. Neostigmine was administered if no fade was detected in the TOF response at the thumb. Deeper blocks were reversed with sugammadex. The prespecified primary and secondary end points were the incidence of PRNB at arrival to the PACU, defined as a normalized TOFR (nTOFR) < 0.9, and severe PRNB, defined as nTOFR <0.7 on arrival to the PACU. Anesthesia providers were blinded to all quantitative measurements made by research staff. Results: Analysis included 163 patients, and 145 underwent orthopedic and 18 abdominal surgeries. Of the 163 patients, 92 (56%) were reversed with neostigmine and 71 (44%) with sugammadex. The overall incidence of PRNB at PACU arrival was 5 of 163 or 3% (95% confidence interval [CI], 1-7). The incidence of severe PRNB in PACU was 1% (95% CI, 0-4). Three of the 5 subjects with PRNB had TOFR <0.4 at time of reversal but were given neostigmine since anesthesia providers detected no fade by qualitative assessment. Conclusions: The use of a protocol that specifies rocuronium dosing and selective use of sugammadex versus neostigmine based on qualitative assessment of TOF count and fade allowed us to achieve an incidence of PRNB of 3% (95% CI, 1-7) at PACU arrival. Quantitative monitoring may be needed to further reduce this incidence.
Association between reversal agents (sugammadex vs. neostigmine) for neuromuscular block and postoperative pulmonary complications: A retrospective analysis

Aolin Ren,Meihan Fan,Zhen Gu,Xiao Liang,Liuhang Xu,Chengjun Liu,Dutian Wang,Hanxuan Chang,Minmin Zhu

DOI: https://doi.org/10.1111/bcp.16056

2024-04-09

British Journal of Clinical Pharmacology

Abstract:Aims Residual neuromuscular blockade has been linked to pulmonary complications in the postoperative period. This study aimed to determine whether sugammadex was associated with a lower risk of postoperative pulmonary complications (PPCs) compared with neostigmine. Methods This retrospective cohort study was conducted in a tertiary academic medical center. Patients ≥18 year of age undergoing noncardiac surgical procedures with general anesthesia and mechanical ventilation were enrolled between January 2019 and September 2021. We identified all patients receiving rocuronium and reversal with neostigmine or sugammadex via electronic medical record review. The primary endpoint was a composite of PPCs (including pneumonia, atelectasis, respiratory failure, pulmonary embolism, pleural effusion, or pneumothorax). The incidence of PPCs was compared using propensity score analysis. Results A total of 1786 patients were included in this study. Among these patients, 976 (54.6%) received neostigmine, and 810 (45.4%) received sugammadex. In the whole sample, PPCs occurred in 81 (4.54%) subjects (7.04% sugammadex vs. 2.46% neostigmine). Baseline covariates were well balanced between groups after overlap weighting. Patients in the sugammadex group had similar risk (overlap weighting OR: 0.75; 95% CI: 0.40 to 1.41) compared to neostigmine. The sensitivity analysis showed consistent results. In subgroup analysis, the interaction P‐value for the reversal agents stratified by surgery duration was 0.011. Conclusion There was no significant difference in the rate of PPCs when the neuromuscular blockade was reversed with sugammadex compared to neostigmine. Patients undergoing prolonged surgery may benefit from sugammadex, which needs to be further investigated.

pharmacology & pharmacy
Retrospective observational study of the effects of residual neuromuscular blockade and sugammadex on motor-evoked potential monitoring during spine surgery in Japan

Hironobu Hayashi,Miki Yamada,Kotoba Okuyama,Tsunenori Takatani,Hideki Shigematsu,Yasuhito Tanaka,Masahiko Kawaguchi

DOI: https://doi.org/10.1097/MD.0000000000030841

2022-09-30

Abstract:Given neuromuscular blockade (NMB) can affect the amplitude and detection success rate of motor-evoked potentials (MEP), sugammadex may be administered intraoperatively. We evaluated the factors affecting the degree of residual NMB (i.e., the train-of-four [TOF] ratio) and the relationship between TOF ratio and MEP detection success rate in Japanese patients undergoing spine surgery. This single-center retrospective observational study included adults who underwent spine surgery under propofol/remifentanil anesthesia, received rocuronium for intubation, and underwent myogenic MEP monitoring after transcranial stimulation. TOF ratios were assessed using electromyography. Sugammadex was administered after finishing the MEP setting and the TOF ratio was ≤0.7. To identify factors affecting the TOF ratio, TOF ratio and MEP detection success rate were simultaneously measured after finishing the MEP setting; to compare the time from intubation to the start of MEP monitoring after NMB recovery between sugammadex and spontaneous recovery groups, multivariable analyses were performed. Of 373 cases analyzed, sugammadex was administered to 221 (59.2%) cases. Age, blood pressure, hepatic impairment, and rocuronium dose were the main factors affecting the TOF ratio. Patients with higher TOF ratios (≥0.75) had higher MEP detection success rates. The time from intubation to the start of MEP monitoring after NMB recovery was significantly shorter in patients administered sugammadex versus patients without sugammadex (P < .0001). The MEP detection success rate was higher in patients with a TOF ratio of ≥0.75. Sugammadex shortened the time from intubation to the start of MEP monitoring after NMB recovery.
Incidence of Postoperative Residual Neuromuscular Blockade after General Anesthesia: a Prospective, Multicenter, Anesthetist-Blind, Observational Study

Buwei Yu,Baoyi Ouyang,Shengjin Ge,Yan Luo,Jun Li,Dongmei Ni,Shuangfei Hu,Hui Xu,Jin Liu,Su Min,Longyun Li,Zhengliang Ma,Kangjie Xie,Changhong Miao,Xinmin Wu

DOI: https://doi.org/10.1185/03007995.2015.1103213

2015-01-01

Current Medical Research and Opinion

Abstract:OBJECTIVE:Evidences demonstrate that postoperative residual neuromuscular blockade (rNMB) is a primary and frequent anesthetic risk factor for postoperative complications. This study was designed to mitigate the paucity of data regarding the occurrence and degree of rNMB in a real-life setting.METHODS:This prospective, multicenter, anesthetist-blind, observational study enrolled 1571 Chinese adults undergoing elective open or laparoscopic abdominal surgery lasting ≤4 hours from 32 hospitals across China. The patients received anesthesia in accordance with routine practice at the study site. Neuromuscular blockade (NMB) was monitored using acceleromyography, with rNMB defined as a train-of-four (TOF) ratio <0.9.RESULTS:The patients' mean age was 46 years and 71% were female. The procedures included laparoscopic (67%), open abdominal (31%), and laparoscopic to open abdominal (2%). NMB was reversed with neostigmine in 78% of patients. The overall incidence of rNMB at extubation was 57.8%, and the proportions of participant with TOF ratios <0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9 were 22.9%, 6.9%, 11.1% and 16.9%, respectively, immediately prior to endotracheal extubation. Age <45 years (OR = 0.630, 95% CI = 0.496-0.801, p = 0.002), use of one neuromuscular blocking agent (NMBA) (OR = 0.387, 95% CI = 0.243-0.618, p < 0.0001), time from neostigmine administration to endotracheal extubation ≥10 min (OR = 0.513, 95% CI = 0.400-0.658, p < 0.0001) and time from last NMBA administration to endotracheal extubation ≥60 min (OR = 0.902, 95% CI = 0.801-0.989, p = 0411) were correlated with non-rNMB at the time of extubation.CONCLUSIONS:This observational study demonstrated that the overall incidence of rNMB at the time of endotracheal extubation was high in Chinese patients undergoing abdominal procedures, which necessitates appropriate management in current real-life practice.CLINICAL TRIAL REGISTRY NUMBER:NCT01871064.
Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis

Young-Sung Kim,Byung-Gun Lim,Young-Ju Won,Seok-Kyeong Oh,Jung-Suk Oh,Soo-Ah Cho

DOI: https://doi.org/10.3390/medicina57111259

2021-11-17

Medicina

Abstract:Background and Objectives: Sugammadex is widely used in anesthesia to reverse rocuronium-induced neuromuscular blockade (NMB). In patients with compromised kidney function, most drugs show alteration of their pharmacokinetic profile with reduced clearance. The purpose of this article is to examine the efficacy, pharmacokinetics, and safety of sugammadex in end-stage renal disease (ESRD) patients receiving general anesthesia, using a systematic review. Materials and Methods: The databases of PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched for studies comparing the efficacy or safety outcomes of sugammadex administration for the reversal of rocuronium-induced NMB, in ESRD patients (group R) or in those with normal renal function (group N) undergoing surgery under general anesthesia. Results: We identified nine studies with 655 patients—six prospective, case-control studies with 179 patients (89 and 90 in groups R and N) and three retrospective observational studies with 476 ESRD patients. In the six prospective studies, the times taken to reach a train-of-four ratio ≥0.9, 0.8, and 0.7 were significantly longer in group R than in group N (weighted mean difference [95% confidence interval] [min]: 1.14 [0.29 to 2.00], 0.9 [0.24 to 1.57], 0.89 [0.20 to 1.57], respectively). The total plasma clearance of sugammadex was significantly lower in group R than in group N. There was no significant difference in the incidence of NMB recurrence and prolonged time to recovery between the groups. In the three retrospective studies, the possibility of sugammadex-related adverse events appears to be insignificant. Conclusions: Sugammadex may effectively and safely reverse rocuronium-induced NMB in patients with ESRD, although the recovery to a TOF ratio of 0.9 may be prolonged compared to patients with normal renal function. Further studies are needed, considering the small number of studies included and the high heterogeneity of some of the results.

Eliminating residual neuromuscular blockade: a literature review

Residual Neuromuscular Block Remains a Safety Concern for Perioperative Healthcare Professionals: A Comprehensive Review

Residual neuromuscular block in the postanaesthesia care unit: a single-centre prospective observational study and systematic review

Driving Residual Neuromuscular Blockade to Zero: Precision Matters

Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity

Sugammadex vs Neostigmine, a Comparison in Reversing Neuromuscular Blockade: A Narrative Review

[Problem of neuromuscular block reversion: neostigmine and sugammadex]

Trends in the use of neuromuscular blocking agents, reversal agents and neuromuscular transmission monitoring: a single-centre retrospective cohort study

The effect of sugammadex on patient morbidity and quality of recovery after general anaesthesia: a systematic review and meta-analysis

The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: A systematic review

Postoperative residual curarisation: complication or malpractice?

The Incidence of Residual Neuromuscular Block in Pediatrics: A Prospective, Pragmatic, Multi-institutional Cohort Study

Improving Neuromuscular Monitoring Through Education-Based Interventions and Studying Its Association With Adverse Postoperative Outcomes: A Retrospective Observational Study

Clinical Effectiveness and Cost-Effectiveness of Sugammadex for Reversal of Neuromuscular Block: A Rapid Health Technology Assessment

Reversal of neuromuscular block with neostigmine and sugammadex: a retrospective cohort study in two centers using different types of neuromuscular monitoring

Safety of sugammadex for reversal of neuromuscular block

Evaluation of a Protocol for the Management of Maintenance and Reversal of Rocuronium Block Using Neostigmine or Sugammadex

Association between reversal agents (sugammadex vs. neostigmine) for neuromuscular block and postoperative pulmonary complications: A retrospective analysis

Retrospective observational study of the effects of residual neuromuscular blockade and sugammadex on motor-evoked potential monitoring during spine surgery in Japan

Incidence of Postoperative Residual Neuromuscular Blockade after General Anesthesia: a Prospective, Multicenter, Anesthetist-Blind, Observational Study

Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis